Miljan Kuljanin

机构：Western University, Moderna Therapeutics (United States) · ORCID：0000-0002-2157-2441

发表论文 101 篇 · 总被引 2475 次 · h-index 21

代表论文

• De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer (2025 · Nature Communications · 被引 13)
• Abstract ND08: Discovery of FX-909, a first-in-class inverse agonist of the peroxisome proliferator-activated receptor gamma (PPARG) lineage transcription factor, to potentially treat patients with the luminal subtype of advanced urothelial cancer (UC) (2023 · Cancer Research · 被引 8)
• Discovery and characterization of FX-909, a covalent inverse agonist of PPARG rationally designed to impose a powerful repressive bias in PPARG for the treatment of PPARG/RXRA-activated muscle-invasive urothelial cancers (2025 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 3)
• Abstract IA014: Mechanistic insights for the advancement of PPARG inverse agonists in muscle invasive urothelial cancer (2024 · Molecular Cancer Therapeutics · 被引 2)
• Covalent PPARγ inverse agonism by FX-909 reveals mechanistic insights into therapeutic targeting of PPARγ/RXRα-activated urothelial carcinoma (2026 · Cell chemical biology)
• Abstract 5784: Discovery of FX-111, a first-in-class heterobifunctional degrader of transcriptionally active androgen receptor (ARON), to treat patients with AR-driven prostate cancer (2026 · Cancer Research)